Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:VERA 11 December 2025 - 30 December 2025

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics shares fell 2.6% to $54.24 midday Friday in thin post-holiday trading, with no major news driving the move. The stock has recently digested a Biologics License Application filing for atacicept in IgA nephropathy, a resolved public offering, and increased competition in the IgAN market. Trading volume remained light, typical for the year-end period.
26 December 2025
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics shares traded near $46 on December 11, 2025, after announcing a $261 million stock offering at $42.50 per share. The company filed a Biologics License Application for atacicept in IgA nephropathy and reported strong late-stage clinical results. Shares are up nearly 100% in six months, with market cap around $2.9–3.0 billion. The offering is expected to close today.
11 December 2025
·
Go toTop